A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Slides:

Advertisements

Similar presentations

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Advertisements

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD

Pulmonary response in sarcoidosis

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Quantification of emphysema with preoperative computed tomography has stronger association with pulmonary complications than pulmonary function test results.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

SC17.02 Lung Cancer in China: Challenges and Perspectives

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation Alessandro Russo, MD, Tindara.

A Feasibility and Safety Study of Bronchoscopic Thermal Vapor Ablation: A Novel Emphysema Therapy Gregory I. Snell, MD, Peter Hopkins, MBBS, Glen Westall,

Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung Zhigang.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma Filippo Gustavo Dall’Olio, MD, Celeste.

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report Kazutaka Fujita, MD, Yuko.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

MET-Mutated NSCLC with Major Response to Crizotinib

Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection Charlotte Billiet, MD, Stéphanie.

Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months Arturo Navarro-Martin, MD, Samantha Aso, MD, Jon Cacicedo,

Rapidly Progressive Diffuse Cystic Lesions as a Radiological Hallmark of Lung Adenocarcinoma Jian Zhang, MD, Yi-Lin Zhao, MD, Ming-Xiang Ye, MD, Gang.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Atypical Pleuropulmonary Tuberculosis Mimicking a Malignant Disease

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Regional Emphysema Score Predicting Overall Survival, Quality of Life, and Pulmonary Function Recovery in Early-Stage Lung Cancer Patients Jie Dai, PhD,

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Cardiac Dysfunction Caused by Osimertinib

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Effects of Extended Pleurectomy and Decortication on Quality of Life and Pulmonary Function in Patients With Malignant Pleural Mesothelioma David Burkholder,

Supreme laryngeal mask airway for laparoscopic cholecystectomy in patient with severe pulmonary fibrosis M. Carron, A. Marchet, C. Ori British Journal.

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Prospective Study on Functional Results After Lung-Sparing Radical Pleurectomy in the Management of Malignant Pleural Mesothelioma Servet Bölükbas, MD,

Vamsidhar Velcheti, MD, Manmeet Ahluwalia, MD

Relationship Between Functional Preservation after Segmentectomy and Volume- Reduction Effects after Lobectomy in Stage I Non-small Cell Lung Cancer Patients.

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor–Mutated Lung Cancer Treated with Two Cycles of Erlotinib Brendan.

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Mark F. Berry, MD, Chi-Fu Jeffrey.

S768I Mutation in EGFR in Patients with Lung Cancer

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Ribavirin in Desquamative Interstitial Pneumonia

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

Bronchioloalveolar Carcinoma Presenting as Chronic Progressive Pulmonary Infiltrates in a Woman with HIV: A Diagnosis Worth Making Todd M. Erickson,

Andreas Rimner, MD, Kenneth E. Rosenzweig, MD

Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance) Michael S. Kent,

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

Popcorn in the Lung Journal of Thoracic Oncology

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC- Positive and FISH-Negative ALK Jong-Mu Sun, MD, PhD, Yoon-La Choi,

Is pulmonary function damaged by neoadjuvant lung cancer therapy

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic Oncology Volume 12, Issue 7, Pages e96-e97 (July 2017) DOI: 10.1016/j.jtho.2017.03.008 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 (A) Chest computed tomography images at baseline before nivolumab treatment (left) and after 5 months of nivolumab therapy (right) in a patient with NSCLC with underlying pulmonary fibrosis that reveal a decrease in size of the dominant left hilar mass. (B) Pulmonary function tests before and after treatment with nivolumab. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; Dlco, diffusion capacity of lung for carbon monoxide. Journal of Thoracic Oncology 2017 12, e96-e97DOI: (10.1016/j.jtho.2017.03.008) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions